Metavia's Obesity Drug Selected as LBA at EASL Congress

Presentation of Safety and Tolerability Results
from High-Dose Phase 1 Trial of DA-1726

Metavia, an affiliate of Dong-A ST, announced on May 12 that research results on 'DA-1726'—a dual-acting obesity treatment targeting GLP-1 (glucagon-like peptide) and glucagon—have been selected as a 'Late-Breaking Abstract (LBA)' for poster presentation at the EASL Congress 2026, the annual scientific meeting of the European Association for the Study of the Liver (EASL).

The European Association for the Study of the Liver is a prestigious academic organization where liver disease experts from around the world share the latest guidelines and clinical data on major liver diseases, including MASH (metabolic dysfunction-associated steatotic liver disease), liver cancer, and cirrhosis. This year's EASL Congress 2026 will take place in Barcelona, Spain, from May 27 to 30.

For this poster presentation, Chris Fang, Chief Medical Officer (CMO) of Metavia, will present research findings under the theme, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with Exploratory Noninvasive Liver Assessment."

DA-1726 is a new drug candidate in development as an obesity treatment belonging to the oxyntomodulin analogue class. It acts on both the GLP-1 and glucagon receptors, suppressing appetite, promoting insulin secretion, and increasing basal metabolic rate in peripheral tissues, ultimately leading to weight loss and improved blood glucose control.

Metavia is currently conducting Part 3 of the Phase 1 clinical trial of DA-1726, utilizing both 'One-step' and 'Two-step' dose escalation strategies to confirm safety at higher doses and optimize tolerability, with the goal of obtaining data in the fourth quarter of this year.

Hyungheon Kim, CEO of Metavia, stated, "Having DA-1726's research results selected as a late-breaking abstract at the EASL annual meeting is a meaningful achievement that demonstrates our competitiveness and potential. DA-1726 is being developed as a next-generation obesity treatment with differentiated competitiveness, and through the ongoing Phase 1 Part 3 trial, we plan to determine the optimal dose and tolerability."

Meanwhile, Metavia serves as the R&D hub of Dong-A Socio Group, leading global research, development, and commercialization efforts. The company is developing obesity treatment 'DA-1726' and MASH treatment 'Vanoglifel', among others. It also continues to introduce its competitiveness and growth strategies to global investors and is actively seeking strategic partnership opportunities.

This content was produced with the assistance of AI translation services.